Results and Impact of the Follow-Up of the NeoALTTO Trial
Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
Clinical Pearls
Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
- The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival
- The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not
- This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
